136 related articles for article (PubMed ID: 25974110)
1. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
2. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
[TBL] [Abstract][Full Text] [Related]
3. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.
Huang X; Meng B; Iqbal J; Ding BB; Perry AM; Cao W; Smith LM; Bi C; Jiang C; Greiner TC; Weisenburger DD; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Gascoyne RD; Cook JR; Tubbs RR; Jaffe ES; Armitage JO; Vose JM; Staudt LM; McKeithan TW; Chan WC; Ye BH; Fu K
J Clin Oncol; 2013 Dec; 31(36):4520-8. PubMed ID: 24220563
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
[TBL] [Abstract][Full Text] [Related]
5. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Ide D; Fujino T; Kobayashi T; Egashira A; Miyashita A; Mizuhara K; Isa R; Tsukamoto T; Mizutani S; Uchiyama H; Kaneko H; Uoshima N; Kawata E; Taniwaki M; Shimura Y; Kuroda J
Int J Hematol; 2024 Jun; 119(6):697-706. PubMed ID: 38492199
[TBL] [Abstract][Full Text] [Related]
6. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
[TBL] [Abstract][Full Text] [Related]
7. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
Vega GG; Avilés-Salas A; Chalapud JR; Martinez-Paniagua M; Pelayo R; Mayani H; Hernandez-Pando R; Martinez-Maza O; Huerta-Yepez S; Bonavida B; Vega MI
BMC Cancer; 2015 Oct; 15():722. PubMed ID: 26475474
[TBL] [Abstract][Full Text] [Related]
8. The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL.
Abdelhamid TM; Gaber AA; Abdelfattah RM; Algamal DA; Hamdy O; Mohamed G
Pathol Res Pract; 2024 Jan; 253():154973. PubMed ID: 38101156
[TBL] [Abstract][Full Text] [Related]
9. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Shimada K; Ohmachi K; Machida R; Ota S; Itamura H; Tsujimura H; Takayama N; Shimada T; Kurosawa M; Tabayashi T; Shimoyama T; Ohshima K; Miyazaki K; Maruyama D; Kinoshita T; Ando K; Hotta T; Tsukasaki K; Nagai H
Ann Hematol; 2024 Jun; 103(6):2021-2031. PubMed ID: 38280061
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
Johnson NA; Boyle M; Bashashati A; Leach S; Brooks-Wilson A; Sehn LH; Chhanabhai M; Brinkman RR; Connors JM; Weng AP; Gascoyne RD
Blood; 2009 Apr; 113(16):3773-80. PubMed ID: 19029441
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma: A STROBE-compliant article.
Zhang Y; Wei Z; Li J; Gao R; Liu P
Medicine (Baltimore); 2018 Jul; 97(30):e11719. PubMed ID: 30045337
[TBL] [Abstract][Full Text] [Related]
12. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance].
Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851
[TBL] [Abstract][Full Text] [Related]
13. Diffuse Large B-Cell Lymphoma With Cardiac Invasion Presented as Acute Myocardial Infarction and Left Ventricular Hypertrophy: A Case Report.
Liu Z; Pan X; Mo J; Deng T; Cen T; Wei B; Chen C
J Investig Med High Impact Case Rep; 2024; 12():23247096241253334. PubMed ID: 38747509
[TBL] [Abstract][Full Text] [Related]
14. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
Cooper A; Tumuluru S; Kissick K; Venkataraman G; Song JY; Lytle A; Duns G; Yu J; Kotlov N; Bagaev A; Hodkinson B; Srinivasan S; Smith SM; Scott DW; Steidl C; Godfrey JK; Kline J
J Clin Oncol; 2024 Feb; 42(4):467-480. PubMed ID: 38079587
[TBL] [Abstract][Full Text] [Related]
15. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Hartert KT; Wenzl K; Krull JE; Manske M; Sarangi V; Asmann Y; Larson MC; Maurer MJ; Slager S; Macon WR; King RL; Feldman AL; Gandhi AK; Link BK; Habermann TM; Yang ZZ; Ansell SM; Cerhan JR; Witzig TE; Nowakowski GS; Novak AJ
Leukemia; 2021 Feb; 35(2):522-533. PubMed ID: 32139889
[TBL] [Abstract][Full Text] [Related]
16. Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms.
Yu H; Peng S; Han S; Chen X; Lyu Q; Lei T
Biomed Res Int; 2021; 2021():5514726. PubMed ID: 34250086
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum albumin level in patients with diffuse large B cell lymphoma.
Chen L; Pan L; Liu T
Acta Biochim Pol; 2023 Dec; 70(4):767-776. PubMed ID: 38051992
[TBL] [Abstract][Full Text] [Related]
18. Experience of multi-disciplinary treatment of multiple cerebellar diffuse large B-cell lymphoma: A case report.
Guo Y; Li J; Li M; Li Z; Cui Y; Li Y; Zhao R; Han Q; Yang H; Ma C
Medicine (Baltimore); 2024 Apr; 103(17):e37923. PubMed ID: 38669361
[TBL] [Abstract][Full Text] [Related]
19. High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma.
Hui X; Li L; Xiong W; Liu Y; Li H; Zhang H; Zhao S; Zhang Y
Clin Exp Med; 2024 Apr; 24(1):89. PubMed ID: 38683255
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Differential Expression of Polymerase Eta Gene in Nonresponding Patients With Diffuse Large B-cell Lymphoma.
Sharma A; Das A; Bal A; Srinivasan R; Malhotra P; Prakash G; Kumar R
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):32-36. PubMed ID: 37867373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
